Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma☆A pilot study

Cappa, Federica Mirici; Cantarini, Maria Chiara; Magini, Giulia; Zambruni, Andrea; Bendini, Chiara; Santi, Valentina; Bernardi, Mauro; Trevisani, Franco

doi:10.1016/j.dld.2004.11.002

Cited by 7 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon the title and abstract screening of the remaining articles, only 16 studies were eligible for full-text reading. Eventually, six studies met our inclusion criteria [12, 17–19, 21, 22]. The flow diagram of study selection and screening is shown in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

“…They comprised 357 patients, and most of them were male (83.2%). Two studies used megestrol [18, 21] while the remaining studies utilised megestrol acetate (the acylated derivative of megestrol). The administered dose of megestrol or megestrol acetate was 160 mg in all studies except one study that applied a dose of 320 mg [19].…”

Section: Resultsmentioning

confidence: 99%

“…Five studies used the Child-Pugh score to classify their included participants [12, 18, 19, 21, 22]. Out of 228 patients in the megestrol group, 85 (37.28%) were classified as Child-Pugh A, 73 (32.01%) were on Child-Pugh B, and only 21 (9.21%) participants were assessed as Child-Pugh C. In the control group: 57 (44.18%) out of 129 were Child-Pugh A, 55 (42.63%) Child-Pugh B, and only 15 (11.62%) Child-Pugh C. Four trials used the Eastern Cooperative Oncology Group (ECOG) performance score, and most of the patients (282 [93.06%]) scored 0–2.…”

Section: Resultsmentioning

confidence: 99%

“…In the study conducted by Cappa et al five patients had an increase in size/number of nodules, while three patients had tumour enlargement and metastasis [21]. In contrast, seven patients had a median tumour size reduction of 18%, and one patient had a reduction of tumour size of 40% in the Chao et al trial [17].…”

Section: Resultsmentioning

confidence: 99%

“…In three studies including 76 participants, 42 (55.26%) patients reported improvement in appetite and food intake after receiving megestrol [17, 18, 21].…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature

Rawla

Thandra

Vellipuram

et al. 2018

View full text Add to dashboard Cite

IntroductionHepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. There is as yet no standard therapy for inoperable HCC. We aimed to systematically review all health-related evidence regarding the effectiveness and safety of megestrol in HCC patients.Material and methodsWe conducted a systematic computerised search in PubMed, Scopus, Web of Science, Embase, and Cochrane CENTRAL. All original human studies reporting the efficacy of megestrol in HCC patients were included in our review.ResultsSix studies including 357 patients were finally eligible. The overall mean survival time of 87 megestrol-treated patients, was 9.187 (95% CI 1.134–17.239) months. Eight patients had tumour size enlargement, and eight patients had tumour size reduction. From three studies including 76 patients, 42 patients reported having improvement of appetite and food intake after receiving megestrol. Diverse adverse events were noticed between studies; however, they were tolerable in most of the studies.ConclusionsTo summarise, no conclusive evidence should be declared regarding the effectiveness of megestrol in patients with inoperable HCC. However, previous studies have shown promising results at the level of prolonging the survival rate, tumour size reduction, and improving the quality of life. Therefore, we recommend that future research studies must examine the role of megestrol in large-population, randomised studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…In three studies including 76 participants, 42 (55.26%) patients reported improvement in appetite and food intake after receiving megestrol [17, 18, 21].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature

Rawla

Thandra

Vellipuram

et al. 2018

View full text Add to dashboard Cite

show abstract

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies

2013

View full text Add to dashboard Cite

Background The presence of cirrhosis increases the potential risk of hemorrhage for patients with hepatocellular carcinoma (HCC). We evaluated the relative risk for hemorrhage in patients with HCC treated with anti-angiogenic agents. Patients and Methods We performed a systematic review and meta-analysis of anti-angiogenic studies in HCC from 1995 to 2011. For non-randomized studies we compared bleeding risk with other HCC single-arm studies which did not include an anti-angiogenic agent. To separate disease-specific factors we also performed a comparison analysis with renal cancer studies which evaluated sorafenib. Results Sorafenib was associated with increased bleeding risk compared to control for all grade bleeding events (OR 1.77; 95% CI 1.04, 3.0) but not grade 3–5 events in both HCC and RCC ((OR1.46 95% CI 0.9, 2.36 [p=0.45]). When comparing the risk of bleeding in single-arm phase 2 studies evaluating anti-angiogenic agents, this risk for all events (OR 4.34; 95% CI 2.16, 8.73) was increased compared to control. Conclusions This analysis of both randomized and non-randomized studies evaluating an anti-angiogenic agent in HCC showed that whilst the use of sorafenib was associated with an increased risk of bleeding in HCC, this was primarily for lower grade events and similar in magnitude to the risk encountered in RCC.

show abstract

Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience

Re²,

Doretto³

et al. 2019

Cytokine

View full text Add to dashboard Cite

show abstract

Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma☆A pilot study

Cited by 7 publications

References 19 publications

Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature

Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature

Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies

Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience

Contact Info

Product

Resources

About